Precision drugs for recurrent or metastatic nasopharyngeal carcinoma (Review)
- Authors:
- Renba Liang
-
Affiliations: Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, P.R. China - Published online on: November 3, 2023 https://doi.org/10.3892/etm.2023.12284
- Article Number: 585
This article is mentioned in:
Abstract
 |
 |
 |
|
Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y and Ma J: Nasopharyngeal carcinoma. Lancet. 394:64–80. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Carioli G, Negri E, Kawakita D, Garavello W, La Vecchia C and Malvezzi M: Global trends in nasopharyngeal cancer mortality since 1970 and predictions for 2020: Focus on low-risk areas. Int J Cancer. 140:2256–2264. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Xiao WW, Huang SM, Han F, Wu SX, Lu LX, Lin CG, Deng XW, Lu TX, Cui NJ and Zhao C: Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: Long-term results of a phase 2 study. Cancer. 117:1874–1883. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J, Peng P, Wu X, Lin Q, Xi X, et al: Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: A multicentre, randomised, open-label, phase 3 trial. Lancet. 388:1883–1892. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Ciardiello F and Tortora G: A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res. 7:2958–2970. 2001.PubMed/NCBI | |
|
Lo KW, To KF and Huang DP: Focus on nasopharyngeal carcinoma. Cancer Cell. 5:423–428. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Chan AT, Hsu MM, Goh BC, Hui EP, Liu TW, Millward MJ, Hong RL, Whang-Peng J, Ma BB, To KF, et al: Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol. 23:3568–3576. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Ueda Y, Enokida T, Okano S, Fujisawa T, Ito K and Tahara M: Combination treatment with paclitaxel, carboplatin, and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic nasopharyngeal carcinoma. Front Oncol. 10(571304)2020.PubMed/NCBI View Article : Google Scholar | |
|
Chen C, Zhang X, Zhou Y, Fu S, Lin Z, Hong S and Zhang L: Treatment of recurrent or metastatic nasopharyngeal carcinoma by targeting the epidermal growth factor receptor combined with gemcitabine plus platinum. Cancer Manag Res. 12:10353–10360. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Xu T, Ou X, Shen C and Hu C: Cetuximab in combination with chemoradiotherapy in the treatment of recurrent and/or metastatic nasopharyngeal carcinoma. Anticancer Drugs. 27:66–70. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Sun XS, Liang YJ, Li XY, Liu SL, Chen QY, Tang LQ and Mai HQ: Palliative chemotherapy with or without anti-EGFR therapy for de novo metastatic nasopharyngeal carcinoma: A propensity score-matching study. Drug Des Devel Ther. 13:3207–3216. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Zhao C, Miao J, Shen G, Li J, Shi M, Zhang N, Hu G, Chen X, Hu X, Wu S, et al: Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: A multicentre, open-label, phase II clinical trial. Ann Oncol. 30:637–643. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Zhu Y, Yang S, Zhou S, Yang J, Qin Y, Gui L, Shi Y and He X: Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma. Ther Adv Med Oncol. 12(1758835920953738)2020.PubMed/NCBI View Article : Google Scholar | |
|
Zong JF, Liang QD, Lu QJ, Liu YH, Xu HC, Chen BJ, Guo QJ, Xu Y, Hu CR, Pan JJ and Lin SJ: Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma. BMC Cancer. 21(1274)2021.PubMed/NCBI View Article : Google Scholar | |
|
Chen C, Zhou Y, Zhang X, Fu S, Lin Z, Fang W, Yang Y, Huang Y, Zhao H, Hong S and Zhang L: Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma. Cancer Med. 9:1721–1732. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Chua DT, Wei WI, Wong MP, Sham JS, Nicholls J and Au GK: Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head Neck. 30:863–867. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Ma B, Hui EP, King A, To KF, Mo F, Leung SF, Kam M, Lo YM, Zee B, Mok T, et al: A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy. Cancer Chemother Pharmacol. 62:59–64. 2008.PubMed/NCBI View Article : Google Scholar | |
|
You B, Le Tourneau C, Chen EX, Wang L, Jarvi A, Bharadwaj RR, Kamel-Reid S, Perez-Ordonez B, Mann V and Siu LL: A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma. Am J Clin Oncol. 35:255–260. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Lee SC, Lim SG, Soo R, Hsieh WS, Guo JY, Putti T, Tao Q, Soong R and Goh BC: Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma. Pharmacogenet Genomics. 16:73–74. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Wakisaka N, Wen QH, Yoshizaki T, Nishimura T, Furukawa M, Kawahara E and Nakanishi I: Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma. Laryngoscope. 109:810–814. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Murono S, Inoue H, Tanabe T, Joab I, Yoshizaki T, Furukawa M and Pagano JS: Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci USA. 98:6905–6910. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Elser C, Siu LL, Winquist E, Agulnik M, Pond GR, Chin SF, Francis P, Cheiken R, Elting J, McNabola A, et al: Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol. 25:3766–3773. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Xue C, Huang Y, Huang PY, Yu QT, Pan JJ, Liu LZ, Song XQ, Lin SJ, Wu JX, Zhang JW, et al: Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol. 24:1055–1061. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Jin Y, Shi YX, Cai XY, Xia XY, Cai YC, Cao Y, Zhang WD, Hu WH and Jiang WQ: Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 138:1717–1725. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Hui EP, Ma BBY, King AD, Mo F, Chan SL, Kam MKM, Loong HH, Ahuja AT, Zee BCY and Chan ATC: Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. Ann Oncol. 22:1280–1287. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Lim WT, Ng QS, Ivy P, Leong SS, Singh O, Chowbay B, Gao F, Thng CH, Goh BC, Tan DS, et al: A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma. Clin Cancer Res. 17:5481–5489. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, et al: Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 14:7272–7283. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Hui EP, Ma BBY, Loong HHF, Mo F, Li L, King AD, Wang K, Ahuja AT, Chan CML, Hui CWC, et al: Efficacy, safety, and pharmacokinetics of axitinib in nasopharyngeal carcinoma: A preclinical and phase II correlative study. Clin Cancer Res. 24:1030–1037. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Zhang Y, Luo F, Ma YX, Liu QW, Yang YP, Fang WF, Huang Y, Zhou T, Li J, Pan HM, et al: A Phase Ib study of lucitanib (AL3810) in a cohort of patients with recurrent and metastatic nasopharyngeal carcinoma. Oncologist. 27:e453–e462. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Or YY, Hui AB, To KF, Lam CN and Lo KW: PIK3CA mutations in nasopharyngeal carcinoma. Int J Cancer. 118:1065–1067. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Yip WK, Leong VC, Abdullah MA, Yusoff S and Seow HF: Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma. Oncol Rep. 19:319–328. 2008.PubMed/NCBI | |
|
Ma BB, Goh BC, Lim WT, Hui EP, Tan EH, Lopes Gde L, Lo KW, Li L, Loong H, Foster NR, et al: Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079). Invest New Drugs. 33:985–991. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Ma BB, Lui VW, Hui CW, Lau CP, Wong CH, Hui EP, Ng MH, Cheng SH, Tsao SW, Tsang CM, et al: Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models. Cancer Lett. 343:24–32. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Lu J, Chen XM, Huang HR, Zhao FP, Wang F, Liu X and Li XP: Detailed analysis of inflammatory cell infiltration and the prognostic impact on nasopharyngeal carcinoma. Head Neck. 40:1245–1253. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Lee AZE, Tan LSY and Lim CM: Cellular-based immunotherapy in Epstein-Barr virus induced nasopharyngeal cancer. Oral Oncol. 84:61–70. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A and Allison JP: CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol. 162:5813–5820. 1999.PubMed/NCBI | |
|
Wherry EJ: T cell exhaustion. Nat Immunol. 12:492–499. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Hsu C, Lee SH, Ejadi S, Even C, Cohen RB, Le Tourneau C, Mehnert JM, Algazi A, van Brummelen EMJ, Saraf S, et al: Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-Positive nasopharyngeal carcinoma: Results of the KEYNOTE-028 study. J Clin Oncol. 35:4050–4056. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Stoker SD, Novalić Z, Wildeman MA, Huitema AD, Verkuijlen SA, Juwana H, Greijer AE, Tan IB, Middeldorp JM and de Boer JP: Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 141:1845–1857. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, Xiong J, Li P, Zhao H, Huang Y, et al: Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: Results from two single-arm, phase 1 trials. Lancet Oncol. 19:1338–1350. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Yang Y, Qu S, Li J, Hu C, Xu M, Li W, Zhou T, Shen L, Wu H, Lang J, et al: Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 22:1162–1174. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, et al: Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: An International, multicenter study of the mayo clinic phase 2 consortium (NCI-9742). J Clin Oncol. 36:1412–1418. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Ma Y, Fang W, Zhang Y, Yang Y, Hong S, Zhao Y, Tendolkar A, Chen L, Xu D, Sheng J, et al: A Phase I/II open-label study of nivolumab in previously treated advanced or recurrent nasopharyngeal carcinoma and other solid tumors. Oncologist. 24:891–e431. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Wei XL, Ren C, Wang FH, Zhang Y, Zhao HY, Zou BY, Wang ZQ, Qiu MZ, Zhang DS, Luo HY, et al: A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors. Cancer Commun (Lond). 40:345–354. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Wang FH, Wei XL, Feng J, Li Q, Xu N, Hu XC, Liao W, Jiang Y, Lin XY, Zhang QY, et al: Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: A phase II clinical trial (POLARIS-02). J Clin Oncol. 39:704–712. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, Li J, Shi YR, Jin F, Xu R, et al: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: A multicenter randomized phase 3 trial. Nat Med. 27:1536–1543. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Hua Y, You R, Wang Z, Huang P, Lin M, Ouyang Y, Xie Y, Zou X, Liu Y, Duan C, et al: Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: An open-label single-arm, phase II trial. J Immunother Cancer. 9(e003290)2021.PubMed/NCBI View Article : Google Scholar | |
|
Chia WK, Wang WW, Teo M, Tai WM, Lim WT, Tan EH, Leong SS, Sun L, Chen JJ, Gottschalk S and Toh HC: A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann Oncol. 23:997–1005. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Smith C, Tsang J, Beagley L, Chua D, Lee V, Li V, Moss DJ, Coman W, Chan KH, Nicholls J, et al: Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res. 72:1116–1125. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, Huls MH, Sheehan A, Wu MF, Liu H, et al: Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother. 33:983–990. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Huang J, Fogg M, Wirth LJ, Daley H, Ritz J, Posner MR, Wang FC and Lorch JH: Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. Cancer. 123:2642–2650. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Chia WK, Teo M, Wang WW, Lee B, Ang SF, Tai WM, Chee CL, Ng J, Kan R, Lim WT, et al: Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol Ther. 22:132–139. 2014.PubMed/NCBI View Article : Google Scholar |
